Documentos relacionados

1. Potential bias of preoperative intravitreal anti-VEGF injection for complications of proliferative diabetic retinopathy.
2. Anti-vascular endothelial growth factor for neovascular glaucoma.
3. Visual prognosis and surgical timing of Ahmed glaucoma valve implantation for neovascular glaucoma secondary to diabetic vitrectomy.
4. Outcomes of neovascular glaucoma in eyes presenting with moderate to good visual potential.
5. A systematic review and meta-analysis of randomised controlled trials in the management of neovascular glaucoma: absence of consensus and variability in practice.
6. Comparative efficacy and safety of different anti-VEGF agents combined with different delivery methods for neovascular glaucoma: a systematic review and Bayesian network meta-analysis.
7. Two-year outcomes of patients presenting to Sydney Eye Hospital with neovascular glaucoma.
8. The incidence and risk factors of neovascular glaucoma secondary to proliferative diabetic retinopathy after vitrectomy.
9. Combined vitrectomy, near-confluent panretinal endolaser, bevacizumab and cyclophotocoagulation for neovascular glaucoma - a retrospective interventional case series.
10. RISK FACTORS FOR SURGERY OR BLINDNESS IN NEOVASCULAR GLAUCOMA EYES TREATED WITH ANTI-VEGF INJECTIONS BY A RETINA SPECIALIST.